Saturday, September 5

Browsing: ReceptorPositive

Research

Spatial analyses implicate high stromal tumour-infiltrating CD8+ lymphocytes as a negative predictive marker for chemotherapy in estrogen receptor-positive breast cancer

By NewsCancerJune 24, 20260

Outlining the tumour-immune microenvironments of the Oncotype Dx RSConsidering the consensus view of estrogen receptor-positive, human epidermal growth factor receptor…

Treatments

3 Things You Should Know About Using Selective Estrogen Receptor Degraders in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

By NewsCancerJune 20, 20260

Release Date: May 6, 2026Expiration Date: May 6, 2027Learning ObjectivesUpon successful completion of this activity, you should be better prepared…

Research

Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial

By NewsCancerMay 22, 20260

The phase III FAMILY trial demonstrated a clinically meaningful and statistically significant improvement in PFS with fulvestrant maintenance therapy compared…

Diagnosis

111 The Aurora Kinase A Inhibitor Alisertib Alone or in Combination With Endocrine Therapy for Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Metastatic Breast Cancer (MBC)

By NewsCancerMay 15, 20260

BackgroundAurora kinase A (AURKA) plays an integral role in the mitotic cell cycle, regulating spindle assembly, centrosome function, chromosome alignment,…

Support

119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Breast Cancer (ABC) Treated With Ribociclib (RIB) + Fulvestrant (FUL): A Subgroup Analysis of Patients With Invasive Lobular Carcinoma (ILC)

By NewsCancerMay 11, 20260

BackgroundMONALEESA-3 reported statistically significant overall survival (OS) benefits with ribociclib plus fulvestrant, which were maintained with extended follow-up. Patients with…

Treatments

TIP136 ELEGANT: Elacestrant Versus Standard Endocrine Therapy (ET) in Women and Men With Node-Positive, Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

By NewsCancerMay 3, 20260

BackgroundAdjuvant endocrine therapy (ET) is the standard of care (SOC) for treating estrogen receptor–positive (ER+)/HER2-negative (HER2–) early breast cancer. Despite…

Support

142 Exploratory Biomarker Analysis of Trastuzumab Deruxtecan Versus Physician’s Choice of Chemotherapy in HER2-Low/Ultralow, Hormone Receptor–Positive Metastatic Breast Cancer in DESTINY-Breast06

By NewsCancerApril 30, 20260

BackgroundDESTINY-Breast06 (NCT04494425), a randomized, open-label, phase 3 trial, demonstrated a clinically meaningful progression-free survival (PFS) benefit with trastuzumab deruxtecan (T-DXd)…

Survivors

141 DESTINY-Breast06 Post Hoc Analysis by Physician’s Choice of Chemotherapy: Efficacy and Safety of Trastuzumab Deruxtecan Versus Physician’s Choice of Chemotherapy in Hormone Receptor–Positive, HER2-Low or -Ultralow Metastatic Breast Cancer

By NewsCancerApril 30, 20260

BackgroundDESTINY-Breast06 is a randomized, open-label phase 3 trial in patients with hormone receptor–positive (HR+), HER2-low (immunohistochemistry [IHC] 1+ or IHC…

Support

146 Giredestrant Vs Standard-of-Care Endocrine Therapy as Adjuvant Treatment for Patients With Estrogen Receptor–Positive, HER2-Negative Early Breast Cancer: Results From the Global Phase III lidERA Breast Cancer Trial

By NewsCancerApril 28, 20260

BackgroundAdjuvant endocrine therapy (ET) is the mainstay treatment for estrogen receptor–positive, HER2-negative (ER+/HER2–) early breast cancer. However, up to one-third…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma

Browsing: ReceptorPositive

Spatial analyses implicate high stromal tumour-infiltrating CD8+ lymphocytes as a negative predictive marker for chemotherapy in estrogen receptor-positive breast cancer

3 Things You Should Know About Using Selective Estrogen Receptor Degraders in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial

111 The Aurora Kinase A Inhibitor Alisertib Alone or in Combination With Endocrine Therapy for Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Metastatic Breast Cancer (MBC)

TIP136 ELEGANT: Elacestrant Versus Standard Endocrine Therapy (ET) in Women and Men With Node-Positive, Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

142 Exploratory Biomarker Analysis of Trastuzumab Deruxtecan Versus Physician’s Choice of Chemotherapy in HER2-Low/Ultralow, Hormone Receptor–Positive Metastatic Breast Cancer in DESTINY-Breast06

141 DESTINY-Breast06 Post Hoc Analysis by Physician’s Choice of Chemotherapy: Efficacy and Safety of Trastuzumab Deruxtecan Versus Physician’s Choice of Chemotherapy in Hormone Receptor–Positive, HER2-Low or -Ultralow Metastatic Breast Cancer

146 Giredestrant Vs Standard-of-Care Endocrine Therapy as Adjuvant Treatment for Patients With Estrogen Receptor–Positive, HER2-Negative Early Breast Cancer: Results From the Global Phase III lidERA Breast Cancer Trial

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma

<![CDATA[Conclusions and Award Ceremony]]>

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma

<![CDATA[Conclusions and Award Ceremony]]>

Latest Post

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1

Managing High-Risk BCLC-C HCC in a Younger Fit Patient

CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma

Subscribe to Updates

What's Hot

Browsing: ReceptorPositive